New York, NY -- (SBWIRE) -- 12/31/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), ImmunoGen, Inc. (NASDAQ:IMGN), Vitran Corporation, Inc. (USA) (NASDAQ:VTNC)
Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) moved up 1.11% on Monday after it declared that final results of its modified 'Dutch auction' self-tender offer to repurchase up to $200 million of its ordinary shares, which expired on December 23.
Can Investors Bet on TARO after this News update? Find out in this Research Report
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) shares plunged over 1.92% on Monday after it released that the target enrollment of 620 patients with advanced soft tissue sarcoma was met in its pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug.
Is THLD a Solid Investment at These Levels? Read This Report For Details
A developer of targeted anticancer therapeutics, ImmunoGen, Inc. (NASDAQ:IMGN) plunged over 1.6% on Monday after it released that it has hired David Johnston as Executive Vice President and Chief Financial Officer, effective today.
How Should Investors Trade IMGN Now? Don’t Miss out a Special Trend Analysis
A Canadian less-than-truckload transportation firm, Vitran Corporation, Inc. (USA) (NASDAQ:VTNC) plunged over 3.44% on Friday as it released it has entered into a definitive arrangement contract with TransForce Inc. pursuant to which TransForce has decided to purchase all of the outstanding common shares of Vitran not already owned by TransForce for $6.50 in cash per share.
What VTNC’s Charts Are Signaling for Traders? Find Out Here
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)